Difference between revisions of "Rosai-Dorfman-Destombes disease"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "=Guidelines=" to "=Guidelines= '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.'''") |
Warner-admin (talk | contribs) m (Text replacement - "https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf" to "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1502") |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 11: | Line 11: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
| − | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
==Consensus guidelines== | ==Consensus guidelines== | ||
*'''2018:''' Abla et al. [http://www.bloodjournal.org/content/131/26/2877.long Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease] [https://pubmed.ncbi.nlm.nih.gov/29720485/ PubMed] | *'''2018:''' Abla et al. [http://www.bloodjournal.org/content/131/26/2877.long Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease] [https://pubmed.ncbi.nlm.nih.gov/29720485/ PubMed] | ||
==[https://www.nccn.org NCCN]== | ==[https://www.nccn.org NCCN]== | ||
| − | *''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/ | + | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1502 NCCN Guidelines - Histiocytic Neoplasms].'' |
=All lines of therapy= | =All lines of therapy= | ||
Revision as of 23:51, 6 May 2024
| Section editor | |
|---|---|
 |
Gaurav Goyal, MD UAB Birmingham, AL, USA |
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
Consensus guidelines
- 2018: Abla et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease PubMed
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Histiocytic Neoplasms.
All lines of therapy
Cobimetinib monotherapy
Regimen
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Diamond et al. 2019 (MSK 15-216) | 2016-NR | Phase 2, fewer than 20 pts in this arm (RT) |
Note: there were N=2 patients with this type of histiocytosis.
References
- MSK 15-216: Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02649972